Results 11 to 20 of about 76,872 (109)

Future of Antiretroviral Drugs and Evolution of HIV-1 Drug Resistance

Viruses, 2023
Highly active antiretroviral (ARV) therapy has been used for many years, but the use in low- and middle-income countries of antiretroviral drugs with low genetic barrier to resistance, combined with limited availability of viral load testing, has led to ...
Charlotte Charpentier, Quentin Le Hingrat, Valentine Marie Ferré, Florence Damond, Diane Descamps   +4 more
doaj   +1 more source

Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy. [PDF]

PLoS Medicine, 2008
BACKGROUND: Transmitted HIV-1 drug resistance can compromise initial antiretroviral therapy (ART); therefore, its detection is important for patient management.
Jeffrey A Johnson, Jin-Fen Li, Xierong Wei, Jonathan Lipscomb, David Irlbeck, Charles Craig, Amanda Smith, Diane E Bennett, Michael Monsour, Paul Sandstrom, E Randall Lanier, Walid Heneine   +11 more
doaj   +1 more source

The prevalence of HIV-1 drug resistance among antiretroviral treatment naïve individuals in mainland China: a meta-analysis. [PDF]

PLoS ONE, 2014
BACKGROUND: Surveillance of drug resistance in antiretroviral treatment-naïve patients in China is needed to ensure optimal treatment outcomes and control of the human immunodeficiency virus (HIV) epidemic.
Yingying Su, Fujie Zhang, Huixin Liu, M Kumi Smith, Lin Zhu, Jing Wu, Ning Wang   +6 more
doaj   +1 more source

Characterization of Human Immunodeficiency Virus-1 Transmission Clusters and Transmitted Drug-Resistant Mutations in Croatia from 2019 to 2022

Viruses, 2023
Molecular epidemiology of HIV-1 infection is challenging due to the highly diverse HIV-genome. We investigated the genetic diversity and prevalence of transmitted drug resistance (TDR) followed by phylogenetic analysis in 270 HIV-1 infected, treatment ...
Ana Planinić, Josip Begovac, Filip Rokić, Petra Šimičić, Maja Oroz, Katja Jakovac, Oliver Vugrek, Snjezana Zidovec-Lepej   +7 more
doaj   +1 more source

HIV-1 drug-resistance surveillance among treatment-experienced and -naïve patients after the implementation of antiretroviral therapy in Ghana. [PDF]

PLoS ONE, 2013
BACKGROUND: Limited HIV-1 drug-resistance surveillance has been carried out in Ghana since the implementation of antiretroviral therapy (ART). This study sought to provide data on the profile of HIV-1 drug resistance in ART-experienced and newly ...
Nicholas I Nii-Trebi, Shiro Ibe, Jacob S Barnor, Koichi Ishikawa, James A M Brandful, Sampson B Ofori, Shoji Yamaoka, William K Ampofo, Wataru Sugiura   +8 more
doaj   +1 more source

High Levels of Transmitted HIV Drug Resistance in a Study in Papua New Guinea.

PLoS ONE, 2017
IntroductionPapua New Guinea is a Pacific Island nation of 7.3 million people with an estimated HIV prevalence of 0.8%. ART initiation and monitoring are guided by clinical staging and CD4 cell counts, when available.
Evelyn Lavu, Ellan Kave, Euodia Mosoro, Jessica Markby, Eman Aleksic, Janet Gare, Imogen A Elsum, Gideon Nano, Petronia Kaima, Nick Dala, Anup Gurung, Silvia Bertagnolio, Suzanne M Crowe, Mark Myatt, Anna C Hearps, Michael R Jordan   +15 more
doaj   +1 more source

The emergence of HIV transmitted resistance in Botswana: "when will the WHO detection threshold be exceeded?". [PDF]

PLoS ONE, 2007
The Botswana antiretroviral program began in 2002 and currently treats 42,000 patients, with a goal of treating 85,000 by 2009. The World Health Organization (WHO) has begun to implement a surveillance system for detecting transmitted resistance that ...
Raffaele Vardavas, Sally Blower
doaj   +1 more source

Transmitted drug resistance in patients with acute/recent HIV infection in Brazil

Brazilian Journal of Infectious Diseases, 2017
Introduction: The widespread use of antiretroviral therapy increased the transmission of antiretroviral resistant HIV strains. Antiretroviral therapy initiation during acute/recent HIV infection limits HIV reservoirs and improves immune response in HIV ...
Ana Cristina G. Ferreira, Lara E. Coelho, Eduarda Grinsztejn, Carlos S. de Jesus, Monick L. Guimarães, Valdiléa G. Veloso, Beatriz Grinsztejn, Sandra W. Cardoso   +7 more
doaj   +1 more source

Evolution of primary HIV drug resistance in a subtype C dominated epidemic in Mozambique. [PDF]

PLoS ONE, 2013
In Mozambique, highly active antiretroviral treatment (HAART) was introduced in 2004 followed by decentralization and expansion, resulting in a more than 20-fold increase in coverage by 2009. Implementation of HIV drug resistance threshold surveys (HIVDR-
Dulce Celina Adolfo Bila, Peter Young, Harriet Merks, Adolfo Salvador Vubil, Mussagy Mahomed, Angelo Augusto, Celina Monteiro Abreu, Nédio Jonas Mabunda, James I Brooks, Amilcar Tanuri, Ilesh Vinodrai Jani   +10 more
doaj   +1 more source

Sentinel surveillance of HIV-1 transmitted drug resistance, acute infection and recent infection. [PDF]

PLoS ONE, 2011
HIV-1 acute infection, recent infection and transmitted drug resistance screening was integrated into voluntary HIV counseling and testing (VCT) services to enhance the existing surveillance program in San Francisco.
Hong-Ha M Truong, Timothy A Kellogg, Willi McFarland, Brian Louie, Jeffrey D Klausner, Susan S Philip, Robert M Grant   +6 more
doaj   +1 more source